Home › Results from Investigational IMPROVE-IT Study of VYTORIN (ezetimibe and simvastatin) Published in the New England Journal of Medicine
 

Keywords :   


Results from Investigational IMPROVE-IT Study of VYTORIN (ezetimibe and simvastatin) Published in the New England Journal of Medicine

2015-06-03 23:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Tracy Ogden, (267) 305-2301orInvestor:Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of results study journal

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
17.05Pornhub partners with UK child abuse fighting charity
16.05CFTC charges Agridime and its co-founders with a fraudulent cattle scheme
16.05Baleage: Advantageous for first cutting hay
More »